Licensing status

Publication and contact information



Not applicable

Mouse and human studies suggest radioiodinated alkylphosphocholine analogs containing 131I or 124I could be used to treat and image tumors, respectively. In xenograft mouse models of cancer, i.v. infusion of 131I-CLR1404 decreased tumor growth and increased survival compared with unlabeled CLR1404. In genetic and xenograft mouse models of various cancers, the analog 124I-CLR1404 could be imaged by PET in primary and metastatic tumors but showed little uptake by benign and premalignant tumors. In a patient with non-small cell lung cancer (NSCLC) and a patient with glioma, tumors and metastases were visualized with PET using 124I-CLR1404. Ongoing work includes evaluating the blood brain barrier permeability of the analogs and designing clinical trials to evaluate the compounds for imaging, radiotherapy and intraoperative tumor margin detection (see New route for old cancer agents,
page 6).

SciBX 7(27); doi:10.1038/scibx.2014.791
Published online July 17, 2014

Covered by issued and filed patents; available for licensing

Weichert, J.P. et al. Sci. Transl. Med.; published online June 11, 2014;
Contact: John S. Kuo, University of Wisconsin School of Medicine and Public Health, Madison, Wis.
Contact: Jamey P. Weichert, Cellectar Biosciences Inc., Madison, Wis.